This means that certain medicines, like those used for cancer treatment, can sometimes harm your heart. It's like the medicine is causing the heart to not work properly, which can be serious. Doctors watch for this carefully when you take these types of treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Carvedilol for Heart Damage?
Heart damage from cancer treatment, called cardiotoxicity, happens when chemotherapy, targeted drugs, immunotherapy or radiation to the chest harms the heart or blood vessels. The most familiar form is a weakening of the heart muscle, which makes it harder for the heart to pump blood and can lead to heart failure. Cancer treatment can also raise blood pressure, disturb the heart's rhythm, inflame the heart muscle (myocarditis), or damage arteries and heart valves. It can appear during treatment or years after it ends, and early damage often causes no symptoms at all. That is why cancer teams check the heart before and during certain treatments. Heart problems matter for two reasons: they can interrupt cancer treatment, and they are a leading health concern for people who survive cancer.
Risk depends mostly on which treatment someone receives and how much of it. Anthracyclines, a group of chemotherapy drugs that includes doxorubicin and is used for breast cancer, lymphoma, leukemia and sarcoma, damage heart muscle in a dose-dependent way: the more someone receives over their lifetime, the higher the risk. Trastuzumab (Herceptin) and other drugs that target the HER2 protein in some breast and stomach cancers can weaken the heart, especially when given with or after an anthracycline. Immune checkpoint inhibitors, such as pembrolizumab (Keytruda), release the brakes on the immune system and occasionally cause it to attack the heart. Radiation that passes through the heart, as in some treatments for breast cancer, lymphoma and other cancers in the chest, can damage arteries, valves and the heart's lining over the long term. Several other cancer drugs can raise blood pressure, narrow blood vessels or affect heart rhythm. A person's own heart health also matters. Existing heart disease, high blood pressure, diabetes, high cholesterol, smoking, obesity, older age and earlier cardiotoxic treatment all raise the chance of trouble. Treatment can also work indirectly, by worsening these risk factors. Adults who were treated for cancer as children carry a lasting higher risk. These factors raise the odds but do not mean damage will occur.
Diagnosis often starts before cancer treatment does. For treatments known to affect the heart, the care team reviews heart history and risk factors, checks blood pressure, cholesterol and blood sugar, and often records an electrocardiogram (ECG), a tracing of the heart's electrical rhythm. Many people also have a baseline echocardiogram, an ultrasound of the heart, so later results can be compared with their own starting point. The key number on an echocardiogram is the left ventricular ejection fraction (LVEF), the share of blood the main pumping chamber pushes out with each beat. A healthy heart usually ejects at least half its blood. Clinicians look for a meaningful drop from a person's own baseline: a fall of 10 percentage points or more to between 40% and 49% counts as moderate damage, and a fall below 40% as severe. A newer echo measurement called strain, and blood tests for troponin (released when heart muscle is injured) and natriuretic peptides (released when the heart is under strain), can pick up injury before the ejection fraction changes. Cardiac MRI or a nuclear scan is used when an echocardiogram is unclear, and suspected myocarditis may need MRI or occasionally a small tissue sample of heart muscle. Not every drop means cancer treatment is to blame. Measurements vary from test to test, and infection, other illness or dehydration can affect results, so changes are usually confirmed and interpreted alongside symptoms.
Prevention comes first. Oncologists use the lowest effective dose of heart-risky drugs, avoid them when an equally effective alternative exists for a high-risk person, and may use dexrazoxane (a heart-protecting medicine given with anthracyclines) or a liposomal form of doxorubicin when high doses are needed. Radiation teams shield the heart with careful planning and techniques such as holding a deep breath during treatment, which moves the heart away from the beam. Controlling blood pressure, cholesterol and diabetes, staying active and stopping smoking all lower risk. Heart medicines are not routinely given just for prevention, though a cardiologist may suggest them for someone at high risk. When damage appears, the decision balances the heart against the cancer. Depending on how serious the change is, the team may continue treatment with closer monitoring, pause or lower the dose, or switch to another drug. Cardiologists, often specialists in cardio-oncology, treat a weakened heart much as they would heart failure from any cause, with medicines such as ACE inhibitors (which relax blood vessels and ease the heart's workload), beta-blockers (which slow the heart and protect the muscle) and diuretics (water pills) to remove extra fluid. Myocarditis from immunotherapy is uncommon, affecting about 1 in 100 people who receive these drugs, but it can be life-threatening, sometimes through dangerous heart rhythms. It is treated urgently with high-dose steroids and sometimes other drugs that calm the immune system, and the immunotherapy is usually stopped. Prompt diagnosis and treatment have greatly improved survival.
The outlook depends on the cause. Weakening linked to trastuzumab is often reversible, and heart function frequently recovers after a pause and heart medicines. Damage from anthracyclines is more often permanent and may need long-term heart medicine and follow-up. Radiation-related problems with arteries, valves or the heart's lining tend to develop slowly and can be hard to reverse; some eventually need procedures or surgery. For many people, a mild drop in heart function caught on a routine scan causes no symptoms and is managed without major change to daily life. Others notice tiring more easily or getting short of breath with effort, and may need to adjust activity while treatment takes effect. The risk does not end with cancer treatment. Some heart problems first appear 5 to 10 years later, and valve disease can take longer. At the end of treatment, ask for a heart surveillance plan. Depending on the drugs and doses received, this may include a repeat echocardiogram about a year after treatment and periodic scans after that, along with yearly checks of blood pressure, cholesterol and blood sugar. Make sure future doctors know which cancer treatments you had.
Ask your cancer team before treatment whether your plan carries heart risk and how your heart will be checked, and arrange a heart review if you are a cancer survivor who has never had a follow-up plan. During or after treatment, contact the care team promptly the same day if you notice new breathlessness with ordinary activity or when lying flat, swelling in the legs or feet, weight gain of more than 3 pounds in a week, or a racing or irregular heartbeat. If you are receiving immunotherapy, also report new muscle weakness or aches, double vision or drooping eyelids, which can accompany heart inflammation. Call 911 for chest pain, fainting, or shortness of breath that is severe or getting rapidly worse.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Heart Damage is like, what's helped you, or ask the community a question.